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Introduction
Optical biopsies have been shown to be very effective in
providing real time, in situ and non-invasive diagnosis of
various tissue pathologies. In the head and neck various
tissues have been interrogated using this modality includ-
ing suspicious oral lesions, tumour resection margins and
metastatic lymph nodes.
Elastic scattering spectroscopy (ESS) is one of the optical
modalities used to identify inflammatory, ischaemic, pre-
malignant and malignant malformation through changes
on the cellular and subcellular level.
The aim of this study was to see if ESS could be used to
identify benign and malignant skin lesions.
Materials and methods
Elastic scattering spectroscopy involves firing a xenon-arc
lamp light into tissues using a fibre-optic probe. Light
undergoes single or multiple scattering events and is then
collected by the same probe. The resultant generated spec-
tra are then compared to gold standard histopathology.
In this study, facial skin lesions acquired from 73 patients
were subjected to in vivo elastic scattering spectroscopy.
Lesions were then surgically resected. The majority of the
lesions were classified into four categories: basal cell carci-
noma, seborrhic keratosis, fibroepithelial polyp and intra-
dermal nevi.
Results
Results showed that ESS can differentiate between normal
and pathological skin conditions as well as benign and
malignant skin conditions.
Conclusion
This technology holds great promise. A larger body of data
is required to achieve higher sensitivity and specificity.
Future data will be acquired from malignant melanoma
lesions to enable comparison with benign pigmented skin
conditions.
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